Peter N Kellogg's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 1,558 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | Peter N. Kellogg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Peter N. Kellogg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Peter N. Kellogg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Peter N. Kellogg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2023 | 4,948 | 4,948 | - | - | Stock Option (right to buy) |